Postmenopausal estrogen replacement therapy and the risk of Alzheimer's disease: a population-based case-control study.
Preliminary animal and human data suggest that estrogens may be protective against Alzheimer's disease in women. In a population-based case-control study at Group Health Cooperative of Puget Sound, Seattle, Washington, the authors compared the exposure of estrogen replacement therapy of 107 female Alzheimer's disease cases with 120 age- and sex-matched controls by using computerized pharmacy data. The cases were obtained from the Alzheimer's Disease Patient Registry of the University of Washington, Seattle, Washington, which is based on the enumerated health plan population from 1987 to 1992. Newly recognized cases of probable Alzheimer's disease according to standardized diagnostic criteria were ascertained, evaluated, and enrolled in the Registry. The controls were selected from the same defined population by stratified random sampling. When the authors applied logistic regression, ever use of estrogens did not show an association with Alzheimer's disease (adjusted odds ratio = 1.1, 95 percent confidence interval 0.6-1.8). Oral and vaginal estrogens yielded similar results. In conclusion, this study provides no evidence that estrogen replacement therapy has an impact on the risk of Alzheimer's disease in women.
Department of Epidemiology, School of Public Health and Community Medicine, University of Washington, Seattle.
D E
DE
Brenner
W A
WA
Kukull
A
A
Stergachis
G
G
van Belle
J D
JD
Bowen
W C
WC
McCormick
L
L
Teri
E B
EB
Larson
D000282:Administration, Intravaginal; D000284:Administration, Oral; D000368:Aged; D000544:Alzheimer Disease / Q000453:epidemiology / Q000209:etiology*; D016022:Case-Control Studies; D015914:Estrogen Replacement Therapy; D005260:Female; D006801:Humans; D016015:Logistic Models; D016017:Odds Ratio; D012307:Risk Factors